2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Pathology, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, APL, MDS, MPN, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

2664 Rapid molecular profiling enables same-week actionable variant detection in 92% of acute leukemia cases: Implications for precision therapy and trial enrollment

Joy Nakitandwe, PhD, MS, Sharan Jhaveri, MD2, Tu Jin Zheng, PhD3, Sheila Shurtleff, PhD4, Jennifer Starbuck, MS5, Akriti G Jain, MD, FACP6, Hetty Carraway, MD, MBA7, Elizabeth M. Azzato, MD8, David Bosler, MD9, Abhay Singh, MD, MPH10
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
7 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States

Background: Earlier molecular characterization in acute myeloid leukemia (AML) diagnosis transforms management by enabling immediate risk stratification, targeted therapy selection, and refined disease classification accordingly. Our institution has piloted a rapid molecular report to deliver actionable results within 5 days of presentation, prioritizing SNV/Indels in FLT3, IDH1/2, NPM1, TP53, KMT2A and recurrent leukemia-defining rearrangements. Conventional molecular and cytogenetic workflows can detect these markers but often rely on multiple reports, duplicate testing, additional specimen collection, and complex care coordination, potentially increasing health care costs and delaying treatment decisions. Rapid, single-report molecular testing that prioritizes clinically actionable alterations may shorten time to results while preserving comprehensive downstream molecular profiling.
Methods: Our molecular pathology laboratory’s acute leukemia NGS-based assay interrogates DNA SNVs/indels across 63 genes and RNA rearrangements involving 107 genes, with comprehensive results reported within 10 days of specimen receipt. To address the need for earlier actionable molecular results, we developed and implemented a modified workflow that streamlines specimen triage, processing, bioinformatics review, and variant interpretation to report priority actionable markers within 5 days using the same specimen. We sought to evaluate whether implementation of the rapid workflow reduced the time to clinically actionable findings and increased enrollment in molecularly guided clinical trials, while preserving delivery of the comprehensive molecular pathology report within 1-2 days.
Results: From October 2024 through July 2026, a total of 304 cases were tested using the rapid molecular workflow. Of these, 283 cases had a confirmed diagnosis of acute leukemia and were included in downstream analysis. The median age was 68 years (Pediatric=14, 4.9%; Adults=269, 95.1%), and most cases were AML (n=213, 75.3%), followed by B-ALL (n=45, 15.9%), acute leukemia NOS (n=21, 7.4%), mixed phenotype acute leukemia (n=3, 1.1%), and T-ALL (n=1, 0.4%). The rapid workflow achieved the 5-day clinical decision window in 92.2% of cases (261/283), with a mean turnaround time of 4.2 days and median of 4 days. Actionable molecular findings were detected in 88.0% of cases (249/283), including NPM1 (n=66, 23.3%), FLT3 (n=63, 22.3%), IDH1/IDH2 (n=63, 22.3%), TP53 (n=51, 18.0%), KMT2A rearrangements (n=31, 11.0%), and BCR::ABL1 (n=29, 10.2%). These rapid results supported risk assessment, therapy selection, and clinical trial screening during the initial critical diagnostic period. Thirty patients (10.6%) were enrolled in clinical trials, exceeding the reported national average of 7.1% and more than 2.6x higher than the 4.1% community program rate (Unger et al.,2024). Clinical trial enrollment increased from 12 cases in 2025 to 17 cases in 2026 (Jan-July), despite fewer rapid cases tested in 2026 than in 2025 (118 vs 155). Only one case was enrolled in 2024. Our rapid molecular testing workflow demonstrated 100% concordance with the subsequent full acute leukemia panel results. The average turnaround time was 4.2 days for the rapid workflow vs 7.3 days for 1,803 cases tested via our laboratory’s standard (non-rapid) acute leukemia NGS workflow during the same period.
Conclusions: A phased molecular genomic testing and reporting workflow applied to an existing acute leukemia NGS test delivered same-week actionable results in 92.2% of cases, identified clinically relevant alterations in 88%, and maintained full concordance with the subsequent comprehensive panel report. By aligning molecular results with the initial therapeutic window, rapid reporting supported early risk-adapted therapy and clinical trial enrollment above our historical rate, likely reflecting trial availability during the study period and will be further characterized in future analyses. Additionally, some actionable opportunities may have been missed during early adoption of rapid reporting, as the treating leukemia team continues to gain familiarity with the assay, alongside variability in trial activation and protocol availability. Beyond trial enrollment, future analyses will assess whether rapid reporting increased use of precision strategies, including IDH-directed combinations and modified treatment approaches for TP53-mutated disease, further defining its impact on precision leukemia care.

Joy Nakitandwe, PhD, MS: No relevant conflicts of interest to declare.